Xenon Operating Cycle from 2010 to 2026
| XENE Stock | USD 42.12 0.67 1.62% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 34.33 | Current Value 64.67 | Quarterly Volatility 119.46701283 |
Check Xenon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xenon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 M, Interest Expense of 6.7 M or Selling General Administrative of 83.2 M, as well as many indicators such as Price To Sales Ratio of 239, Dividend Yield of 0.0 or PTB Ratio of 2.16. Xenon financial statements analysis is a perfect complement when working with Xenon Pharmaceuticals Valuation or Volatility modules.
Xenon | Operating Cycle | Build AI portfolio with Xenon Stock |
Analyzing Xenon Pharmaceuticals's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing Xenon Pharmaceuticals's current valuation and future prospects.
Latest Xenon Pharmaceuticals' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Xenon Pharmaceuticals over the last few years. It is Xenon Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Xenon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Xenon Operating Cycle Regression Statistics
| Arithmetic Mean | 56.70 | |
| Geometric Mean | 22.92 | |
| Coefficient Of Variation | 210.69 | |
| Mean Deviation | 54.74 | |
| Median | 38.15 | |
| Standard Deviation | 119.47 | |
| Sample Variance | 14,272 | |
| Range | 511 | |
| R-Value | 0.08 | |
| Mean Square Error | 15,120 | |
| R-Squared | 0.01 | |
| Significance | 0.75 | |
| Slope | 1.96 | |
| Total Sum of Squares | 228,358 |
Xenon Operating Cycle History
About Xenon Pharmaceuticals Financial Statements
Xenon Pharmaceuticals stakeholders use historical fundamental indicators, such as Xenon Pharmaceuticals' Operating Cycle, to determine how well the company is positioned to perform in the future. Although Xenon Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Xenon Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Xenon Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Xenon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 34.33 | 64.67 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:Check out the analysis of Xenon Pharmaceuticals Correlation against competitors. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Will Biotechnology sector continue expanding? Could Xenon diversify its offerings? Factors like these will boost the valuation of Xenon Pharmaceuticals. Anticipated expansion of Xenon directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Xenon Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.89) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Xenon Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Xenon's accounting equity. The concept of intrinsic value - what Xenon Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Xenon Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Xenon Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.